Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    6 June 2024

    MediMab Biotherapeutics opens bespoke laboratory facilities, created by Kadans Science Partner, at Abingdon Science Park, UK

    New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumours Kadans has also completed on Barton House, a new research...

    31 May 2024

    Time from EMA approval to CT outcome for first indication vs. AMSR

    This post launches a series of infographics focused on pricing and market access trends of rare disease treatments in France. Each post in this series zooms into a specific PMA trend by leveraging RADAR, CRA’s orphan drug data repository that includes all orphan drugs granted EMA approv...

    29 May 2024

    Impact of medicare price “negotiation” program on small and large molecule medicines

    The Inflation Reduction Act (IRA) directs the U.S. federal government to set a “Maximum Fair Price” (MFP) for the medicines with the highest spending in Medicare. The MFP will be implemented for selected small molecule drugs as early as nine years after approval, and as early as 13 year...

    5 June 2024

    VALANX Biotech announces promising results in first in-vivo study of novel protein conjugate therapy

    Study demonstrates pre-clinical efficacy of lead program VLX101 in treating autoimmune disease ...

    4 June 2024

    Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows

    Next-generation assay provides a rapid and cost-effective solution to quantify IgG production in single cells ...

    4 June 2024

    Living with paediatric asthma

    A number of different management techniques can help in controlling asthma in children. The aim of these management techniques is to enable the child to have a “normal life”, free of asthma symptoms. This includes enabling the child to sleep without any asthmatic related disruptions, to...

    3 June 2024

    Sable&Hawkes deliver campaign graphics and new product illustrations for global biotech

    Sable&Hawkes have delivered product and marketing illustrations, icons and infographics for global biopharma and life sciences company Sartorius. ...

    3 June 2024

    SolasCure selected for Innovate UK Global Incubator Programme in Houston

    Programme delivered in partnership with the Texas Medical Centre Programme will support Aurase Wound Gel for future entry into US market, advancing SolasCure’s mission to transform chronic wound care for millions of patients worldwide Cambridge, UK 03 June 2024: SOLASCURE Ltd (Sol...

    3 June 2024

    PhoreMost achieves second milestone in target discovery alliance with Boehringer Ingelheim

    Milestone payment follows successful target identification and validation in separate project under same collaboration Cambridge, UK, 03 June 2024: PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. Th...

    3 June 2024

    DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

    Cambridge and Newcastle UK: DefiniGEN Ltd., and Atelerix Ltd., announces they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Hep...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 141
    • Page 142
    • Current page 143
    • Page 144
    • Page 145
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS